GlassScriptPhysician profile
Thomas John Hegarty
NPI 1730246463
$306.38
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $96.81 · 2021: $69.43 · 2022: $34.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $43.34 | 2019 | |
| Amgen INC. | $35.49 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.26 | 2019-2021 | |
| Genzyme Corporation | $23.76 | 2021 | |
| Dova Pharmaceuticals | $19.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.46 | 2022 | |
| Eisai INC. | $15.01 | 2020 | |
| Clovis Oncology, INC. | $14.78 | 2020 | |
| Pfizer INC. | $14.16 | 2020 | |
| Tesaro, INC. | $13.90 | 2019 | |
| Gilead Sciences, INC. | $13.72 | 2021 | |
| Lilly USA, LLC | $12.03 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.42 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.20 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hegarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.